Outset Medical, Inc.

Dr. Michael  Aragon M.D.

Chief Medical  Officer

Nicole  Shannon

Director of Marketing Communications

Ms. Leslie L. Trigg

President, Chief Executive Officer & Chairman

Mr. John L. Brottem

General Counsel & Secretary

Mr. Nabeel  Ahmed

Chief Financial Officer

Mr. Marc  Nash

Senior Vice President of Operations and R&D

Mr. James S. Mazzola

Head of Investor Relations

Outset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. It provides the Tablo Hemodialysis System, which comprises a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.

SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Outset Medical, Inc. (NASDAQ: OM) securities between August 1, 2022 and August 7, 2024. Outset Medical is a medical technology company.

OM REMINDER – Robbins LLP Reminds OM Stockholders to Obtain Counsel in Light of the Pending Lead Plaintiff Deadline

LOS ANGELES , Oct. 4, 2024 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Outset Medical, Inc. ("Outset Medical" or the "Company") (NASDAQ: OM).

OM Investors Have Opportunity to Lead Outset Medical, Inc. Securities Fraud Lawsuit

LOS ANGELES, CA / ACCESSWIRE / October 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Outset Medical, Inc. ("Outset" or "the Company") (NASDAQ:OM) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 1, 2022 and August 7, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 28, 2024.

Outset Medical Inc Is Being Sued For Possible Securities Fraud And Affected Shareholders Are Urged To Contact The Schall Law Firm

SAN FRANCISCO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Hagens Berman encourages Outset Medical (NASDAQ: OM) investors who suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge who may assist the investigation to contact its attorneys.

Outset Medical (OM) Receives Nasdaq Notice, Shares No Longer Meet Minimum Bid Requirement, Class Action Pending After FDA Warning - Hagens Berman

NEW YORK, Oct. 03, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Outset Medical, Inc. (NASDAQ: OM) between August 1, 2022 and August 7, 2024, both dates inclusive (the “Class Period”), of the important October 28, 2024 lead plaintiff deadline.

Outset Medical, Inc.OM

Outset Medical, Inc.
OM